Antonia DePace

Data from the Circulating Cell-Free Genome Atlas on Clinical limit of detection, or cLOD, may help investigators better detect multiple cancers at earlier stages.

A lack of understanding, communication, and more was expressed among both patients and caregivers regarding a subtype of kidney cancer.

Data from the ARROW study demonstrated safety and efficacy of pralsetinib in a cohort of Chinese patients with RET fusion–positive non–small cell lung cancer.

Retrospective data presented at 2021 EHA revealed potential treatment gaps in the management of patients with myeloproliferative neoplasms.

A higher overall response rate was noted with lifileucel and pembrolizumab versus pembrolizumab alone in patients with checkpoint inhibitor–naïve advanced melanoma, according to phase 2 trial results that were reported at the 2021 ASCO Annual Meeting.

Most patients with either mantle cell lymphoma or chronic lymphocytic leukemia who were treated in a phase 1/2 trial had a response to therapy with the combination of cirmtuzumab plus ibrutinib.

Phase 2 data presented at the 2021 ASCO Annual Meeting indicate that more than half of patients with previously treated advanced colorectal cancer who were treated with pembrolizumab plus lenvatinib were alive at 6 months.

Better adherence to oral chemotherapy was seen in patients who used a smartphone mobile app, according to a presentation at the Oncology Nursing Society’s 46th Annual Congress.